U.S. markets closed

Entasis Therapeutics Holdings Inc. (ETTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.7800-0.0600 (-3.26%)
At close: 4:00PM EST

1.8000 +0.02 (1.12%)
After hours: 6:03PM EST

Sign in to post a message.
  • a
    alan
    With Innoviva already owning 37.3ml shares it is a waiting game. They actually need the SP to go up before a buyout as it would be cheaper for them. (The price of a buyout would be at lower cost to them if the gap between buyout price and SP is less)
    Any thoughts?
  • D
    Douglas
    How high can this get.....realistically???
    Neutral
  • S
    Shlomo
    Market cap laughable 63 million while cash balance is at 62 million so stock trading at Cash and has 2 very Attractive Drugs in Phase 3 with readout in short term .Thats what i call i PURE GIFT ..STRONG BUY
    Presentation
    https://investors.entasistx.com/static-files/0bf75506-2d54-4b14-896a-6a3d5ed53472
  • S
    Seb
    Hi guys. Anyone can break down how much potentially this company make from their phase 3 drug pipeline?
    Market cap of this company right now is tiny. I looked at the presentation but just looking for more info. Thank you.
  • T
    Tony23
    HI ... new to ETTX. What caused the steep decline between mid Sept and early Nov?
  • 2
    2Invest
    this is a great place to be, i will seek 50 000 today, sell me your portion...I will buy and add more of this to my portfolio.
  • S
    Steven
    Do I understand it correctly this trial 3 drug is for treating hospital acquired infection? What other drug will it be competing with?
  • C
    Craig
    The have this pegged at 1.80 for some reason. Interesting
  • S
    Sharron
    Market cap floating pennies above cash in hand. This kind of bargain draws attention.

    Either the extreme short interest is buyout related, or its because someone hopes they can pad their EOY bonus by targeting an illiquid stock with an empty event calendar. The mass hiring and institutional ownership tell us its NOT because the company is in trouble.

    Might want to watch this closely. Definitely short squeeze potential. Otherwise, patience will reward.
    Bullish
  • L
    L.R.
    What is wrong with this stock?
  • s
    sheldon
    Trying to consolidate then this will take off soon to $5.
  • S
    Shlomo
    Strong accumulation ongoing on this one jump to $5 and more coming as we move closer to the important Phase 3 readout expected next Quarter . With positive results this low float stock will move toward $1 Billion valuation or to $25-30 per Share .STRONG BUY
    Bullish
  • s
    smb_gt
    How can ETTX be near its all-time low? looks like a good, small bio-tech...some pipeline in Phase 3 with big partners, small debt, big cash on hand, trading below book value. Everything looks great for ETTX except for the stock price.
  • 1
    1stockatatime
    I suspect a deal is in the works.
  • s
    sheldon
    Any news updates of their pipeline? When will they do press release?
  • A
    Adam
    I like seeing huge volume at the bottom of a bearish channel with analysts targeting this stock in the $5-8 range. Also the stock has not dipped under $2 for 12 months. I'm buying
  • B
    Brent
    Why does this stock make crazy moves pre market and after market. It's $1.85 after market.
  • R
    Roa
    This can not be an investment. It is a trade until it goes below 1 or boom to 5. No options , no news, after market movement. Does anybody understand what is up with this stock?. It is 50% down from 3 range. When you average down it goes down further. Don`t be fooled when it goes up in aftermarket in the next few days.
    Bearish
  • S
    Sharron
    "The stock market is a device for transferring money from the impatient to the patient." ETTX is a telling cog in this device... Two market dominant products cued up for approval next spring. Huge institutional backing. Bipartisan bill designed to financially incentivize antibiotic development in the works. Stock price at all time lows... Gotta love finds like this.
    Bullish
  • S
    Sharron
    Lot's of questions. Why all the departures/openings? Why so much short action on a company already heavily oversold, especially one so well partnered, well funded, and so close to completing two commercially significant phase III trials?

    Something's afoot...
    Bullish